PMID- 12579266
OWN - NLM
STAT- MEDLINE
DCOM- 20030729
LR  - 20051117
IS  - 1021-335X (Print)
IS  - 1021-335X (Linking)
VI  - 10
IP  - 2
DP  - 2003 Mar-Apr
TI  - S-phase kinase-associated protein 2 expression in laryngeal squamous cell 
      carcinomas and its prognostic implications.
PG  - 321-5
AB  - The F-box protein S-phase kinase-associated protein 2 (Skp2) positively regulates 
      the G1-S transition by controlling the stability of several G1 regulators, such 
      as the cell cycle inhibitor p27kip1. However, the clinical significance of Skp2 
      in patients with laryngeal squamous cell carcinoma (LSCC) remains unknown. In 
      this study, a potential distribution of Skp2 in LSCC and its clinical 
      implications was investigated by an immunohistochemical study. Overall, Skp2 
      overexpression was observed in 36.7% (37 of 102) patients and was significantly 
      associated with lymph node metastasis (p=0.002) and was inversely associated with 
      p27kip1 expression (p=0.026). Survival analysis using the Kaplan-Meier method 
      showed that Skp2 overexpression was significantly associated with shorter 
      disease-free and overall survival (p=0.0051 and p=0.0002, respectively). When 
      Skp2 expression and p27kip1 expression were combined, patients with both Skp2 
      overexpression and reduced expression of p27kip1 revealed poorest disease-free 
      and overall survival as compared to the other cases (p=0.0017 and p<0.0001, 
      respectively). Additionally, in early stage (I, II) cases, Skp2 expression was 
      also revealed to possess a significant prognostic factor in overall survival 
      (p=0.0234), but not in disease-free survival (p=0.2055). By multivariate analysis 
      using the Cox proportional hazards model, tumor grade, tumor size, clinical stage 
      and Skp2 expression were independent prognostic factors both in disease-free and 
      overall survival. These findings indicated that Skp2 expression was closely 
      associated with tumor progression and represented an independent marker for 
      prognosis of LSCC.
FAU - Dong, Youyi
AU  - Dong Y
AD  - Department of Physiology, Kagawa Medical University, Kagawa 761-0793, Japan.
FAU - Sui, Li
AU  - Sui L
FAU - Watanabe, Yasuo
AU  - Watanabe Y
FAU - Sugimoto, Katsuyoshi
AU  - Sugimoto K
FAU - Tokuda, Masaaki
AU  - Tokuda M
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Greece
TA  - Oncol Rep
JT  - Oncology reports
JID - 9422756
RN  - 0 (Cell Cycle Proteins)
RN  - 0 (S-Phase Kinase-Associated Proteins)
RN  - 0 (Tumor Suppressor Proteins)
RN  - 147604-94-2 (Cyclin-Dependent Kinase Inhibitor p27)
SB  - IM
MH  - Carcinoma, Squamous Cell/*metabolism/pathology
MH  - Cell Cycle Proteins/*metabolism
MH  - Cyclin-Dependent Kinase Inhibitor p27
MH  - Female
MH  - Genes, Tumor Suppressor
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - Laryngeal Neoplasms/*metabolism/pathology
MH  - Lymphatic Metastasis
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Retrospective Studies
MH  - *S Phase
MH  - S-Phase Kinase-Associated Proteins
MH  - Survival Rate
MH  - Tumor Suppressor Proteins/metabolism
EDAT- 2003/02/13 04:00
MHDA- 2003/07/30 05:00
CRDT- 2003/02/13 04:00
PHST- 2003/02/13 04:00 [pubmed]
PHST- 2003/07/30 05:00 [medline]
PHST- 2003/02/13 04:00 [entrez]
PST - ppublish
SO  - Oncol Rep. 2003 Mar-Apr;10(2):321-5.